Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + leflunomide + sulfasalazine + hydroxychloroquine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
This is a combination therapy of four conventional disease-modifying antirheumatic drugs (DMARDs) used primarily for treating rheumatoid arthritis and other autoimmune conditions. The combination includes methotrexate (the anchor drug in RA treatment), leflunomide (a pyrimidine synthesis inhibitor), sulfasalazine (an anti-inflammatory agent), and hydroxychloroquine (an antimalarial with immunomodulatory properties). This multi-DMARD approach is used when single DMARD therapy is insufficient to control disease activity. The combination works through different mechanisms to suppress the immune system, reduce inflammation, prevent joint damage, and slow disease progression.
- Brand names
- TrexallRheumatrexAzulfidinePlaquenilArava
- Other names
- MTX (for methotrexate)SSZ (for sulfasalazine)HCQ (for hydroxychloroquine)LEF (for leflunomide)
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)
Beyond the preview
Go deeper on methotrexate + leflunomide + sulfasalazine + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + leflunomide + sulfasalazine + hydroxychloroquine.